Jump to content

Proterguride

Add links
From Wikipedia, the free encyclopedia
(Redirected from VUFB 13416)
Proterguride
Clinical data
Other namesVUFB-13416; VUFB13416; ZK-39437; ZK39437; 6-Propylterguride; 6-Propyl-9,10-dihydrolisuride; N,N-Diethyl-N'-(6-propylergolin-8α-yl)urea
Drug classDopamine agonist; Prolactin inhibitor; Antiparkinsonian agent
Identifiers
  • 3-[(6aR,9S,10aR)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H32N4O
Molar mass368.525 g·mol−1
3D model (JSmol)
  • CCCN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NC(=O)N(CC)CC
  • InChI=1S/C22H32N4O/c1-4-10-26-14-16(24-22(27)25(5-2)6-3)12-18-17-8-7-9-19-21(17)15(13-23-19)11-20(18)26/h7-9,13,16,18,20,23H,4-6,10-12,14H2,1-3H3,(H,24,27)/t16-,18+,20+/m0/s1
  • Key:FCRJELOYDVBTGW-ILZDJORESA-N

Proterguride (INNTooltip International Nonproprietary Name; developmental code names VUFB-13416, ZK-39437), also known as 6-propylterguride or 6-propyl-9,10-dihydrolisuride, is a dopamine agonist of the ergoline family described as a prolactin inhibitor and antiparkinsonian agent which was never marketed.[1][2][3][4][5] It is closely structurally related to certain other ergolines like terguride and lisuride.[1][4] Besides dopamine receptors, the drug also interacts with serotonin, adrenergic, and histamine receptors.[5] Proterguride was first described in the literature by at least 1981.[1]

References

[edit]
  1. ^ a b c Elks, J. (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 30 June 2025.
  2. ^ Milne, George (8 May 2018). Drugs: Synonyms and Properties. Routledge. ISBN 978-1-351-78990-5. Retrieved 30 June 2025.
  3. ^ Negwer, Martin (2001). Organic-chemical Drugs and Their Synonyms: An International Survey. Wiley-VCH. ISBN 978-3-527-30247-5. Retrieved 30 June 2025.
  4. ^ a b Ita K (June 2017). "Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases". J Drug Target. 25 (5): 406–419. doi:10.1080/1061186X.2016.1245310. PMID 27701893. Proterguride (N6-propylterguride or N6-propyldihydrolisuride) is an ergoline derivative with potent dopaminergic activity [124, 125]. It has been reported that strong dopaminergic activity can be achieved at plasma concentrations below 50 pg/mL [125]. Physiologic dopamine receptor stimulation in the human striatum can be simulated by continuous administration of proterguride (PT) [125].
  5. ^ a b Schurad B, Horowski R, Jähnichen S, Görnemann T, Tack J, Pertz HH (April 2006). "Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors". Life Sci. 78 (20): 2358–2364. doi:10.1016/j.lfs.2005.09.046. PMID 16310806.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Proterguride&oldid=1298151946"